OncoMatch/Colorectal Cancer (CRC)/MMR / MSI-H
Colorectal Cancer (CRC)MMR / MSI-H Clinical Trials
Mismatch repair deficiency (dMMR), detected by IHC loss of any MMR protein or by PCR/NGS for microsatellite instability-high (MSI-H), defines an immunotherapy-responsive subgroup in approximately 4% of metastatic CRC. Pembrolizumab is first-line standard for dMMR/MSI-H metastatic CRC; nivolumab ± ipilimumab provides an alternative. Trials study neoadjuvant immunotherapy for early-stage dMMR CRC and combinations to address primary resistance.
Top recruiting MMR / MSI-H Colorectal Cancer (CRC) trials
Ranked by phase and US site count.
See all trials matched to your profile →Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
Canadian Cancer Trials Group
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
Centre Hospitalier Universitaire de Besancon
mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC
Jun Huang
Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers
Sun Yat-sen University
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Sun Yat-sen University